Search clinical trials for: 131I-L19SIP Radioimmunotherapy (RIT)

Total 6 results

Philogen S.p.A.

Terminated

Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

Patients With Cancer

Italy, United Kingdom
Philogen S.p.A.
Eudax S.r.l.

Completed

A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Cancer

Italy
Philogen S.p.A.

Completed

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Brain Metastases From Solid Tumors

Italy, United Kingdom
Philogen S.p.A.

Terminated

131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Italy
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States

3

Subscribe